Parse

Parse indexes AI recommendations so brands know where they stand.

Products

  • Brands
  • Markets
  • Integrations
  • Work with us
  • Pricing
  • MCP

Resources

  • Research
  • Methodology
  • Blog

© 2026 Parse. All rights reserved.

LegalPrivacy PolicyTerms of Service
Parse
Work with usPricing
Sign inCheck your brand
  1. Brands
  2. Unlearn.AI
BrandsUnlearn.AI

How AI describes Unlearn.AI

Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this

Unlearn.AI logoUnlearn.AIunlearn.ai

Unlearn provides an AI-powered platform that uses digital twins, data, and modeling to help clinical trial teams plan, monitor, and analyze studies with greater confidence. The platform integrates evidence and reasoning to reduce trial size, cost, and time, and is trusted by leading biopharma companies for applications in neuroscience, immunology, and metabolic disease.

Parse Score

43.4
Strength8
Reach26
Authority21

Work at Unlearn.AI?

Claim this profile for the full report: every prompt where Unlearn.AI appears, who is gaining, and what AI says about you. Claiming is free and unlocks your brand’s ambient view. Monitoring a market is the paid layer on top.

Verified with a work email.

Track this weekly.

Monitor Unlearn.AI

Words AI uses

AI reaches for pioneering · ai-generated digital twins · ai-generated synthetic control arms when it describes Unlearn.AI.

Sources

unlearn.ai shapes more of what AI says about Unlearn.AI than any other source, at 20% of its citations.

linkedin.com · casrai.org · drugtargetreview.com · aicerts.ai

AI questions where Unlearn.AI appears

Always know where you stand in AI

Start monitoring Unlearn.AI

  • Excerpts where Unlearn.AI appeared in the AI's answer

    Google AI Mode · excerpt
    Unlearn.AI is a prominent platform that uses AI-generated "digital twins" to create synthetic control arms
    Google AI Mode · excerpt
    Unlearn.AI: They specialize in creating digital twins —AI-generated virtual patients that predict how a patient would progress on a placebo